Table of Contents
- 01Introduction
- 02The Statistical Analysis Plan Comes First
- 03Sample Size Is a Negotiation With Reality
- 04Interim Looks and the Firewall
- 05Working With Statistical Programmers
- 06Defending the Numbers to Regulators
- 07Estimands and the ICH E9(R1) Shift
- 08Where the Role Sits, and How People Get Into It
- 09Skills Hiring Managers Are Looking For Right Now
- 10How the Career Ladder Typically Runs
- 11Conclusion
Introduction
Ask most people what a biostatistician does on a clinical trial and you'll get a vague answer about "crunching numbers." That undersells the job badly. A clinical trial biostatistician is the person who decides, before a single patient is enrolled, exactly how the trial's central question will be answered with data — and then defends that answer, line by line, when a regulatory reviewer or a data monitoring committee pushes back. The role is distinct from statistical programming and from clinical data management, even though all three sit close together on an org chart and get confused constantly by people outside clinical development.
This is a look at what actually fills a biostatistician's week: the document that locks in the plan before anyone sees unblinded data, the firewall that separates who can see what and when, and the slow accumulation of judgment calls that determine whether a trial's result holds up under scrutiny.
The Statistical Analysis Plan Comes First
Long before database lock, the biostatistician writes — or leads the writing of — the Statistical Analysis Plan (SAP). This document translates the protocol's objectives into specific, pre-specified analyses: which test statistic answers the primary endpoint, how missing data will be handled, what the multiplicity strategy is if there are multiple endpoints or dose arms, and which subgroups will be examined and how those findings will be labeled (confirmatory versus exploratory).
The SAP matters because it is signed and finalized before the study is unblinded. That sequencing is the whole point: it prevents a sponsor from seeing the data first and then picking the analysis that makes the result look best. A biostatistician who writes a vague or incomplete SAP creates problems that surface months later, usually in a regulatory review letter asking why an analysis that appears in the clinical study report wasn't pre-specified.
92 open now
Clinical operations roles
Clinical Operations Associate DirectorBridgeBioRemote, US$191K
Senior Clinical Trials Systems ManagerNateraRemote, US$142K
Associate Technical Liaison, Clinical TrialsLabcorpIndianapolis, IN · Hybrid
Study Start Up Manager - IQVIA BiotechIQVIADurham, NC$58K–$216K
Sample Size Is a Negotiation With Reality
Deciding how many patients a trial needs is one of the biostatistician's earliest and most consequential contributions. The calculation depends on the expected effect size, the variability of the endpoint, the significance level, and the desired statistical power — usually 80% or 90% power to detect a difference if one truly exists. Each of those inputs is an assumption, and assumptions are where the real conversations happen.
A clinical team wants a smaller, faster, cheaper trial. The biostatistician's job is to show what that choice costs in the ability to detect a true effect, or in the risk of a false positive. Sample size re-estimation — built into some adaptive designs — lets a trial adjust its enrollment target partway through based on observed variability, without unblinding treatment assignment. Designing that correctly, so it doesn't inflate the false-positive rate, is specialist work.
Interim Looks and the Firewall
Many trials, especially longer ones or those in serious conditions, include interim analyses: planned looks at the accumulating data before the trial ends, usually to check for overwhelming efficacy, futility, or safety concerns that would make continuing unethical. These looks are where the discipline's most rigorous safeguards live.
An unblinded statistician — someone walled off from the day-to-day study team — prepares the interim analysis and presents it to an independent Data Safety Monitoring Board (DSMB). The study team, including the trial's own lead biostatistician in many designs, never sees unblinded results. This firewall exists because knowing an interim result, even partially, can unconsciously change how a study team runs the rest of the trial. Alpha spending functions — methods like O'Brien-Fleming or Pocock boundaries — are built into the SAP specifically to control how much of the trial's overall false-positive budget gets "spent" at each interim look, so that stopping early for efficacy doesn't inflate the risk of a wrong conclusion.
Working With Statistical Programmers
The biostatistician designs the analysis; a statistical programmer — often, but not always, a separate role — writes the code that executes it, typically in SAS or R. The programmer builds the ADaM (Analysis Data Model) datasets from the raw collected data, following CDISC standards that regulators now expect as part of a submission. From those datasets come the tables, listings, and figures (TLFs) that populate the clinical study report.
In smaller biotechs, one person may do both jobs. In larger organizations and most CROs, the two are separate career tracks with their own hiring pipelines — programmers often come from a computer science or applied statistics background with deep SAS fluency, while biostatisticians typically hold a graduate degree with heavier theoretical statistics training. Either way, the working relationship is iterative: draft tables go back and forth, discrepancies get traced to their source, and the final numbers in a submission have usually been checked by more than one person independently.
Defending the Numbers to Regulators
A biostatistician's work doesn't end at database lock. During regulatory review, agencies route statistical questions to the sponsor's biostatistics function directly — not relayed secondhand through regulatory affairs. Preparing responses to an FDA or EMA statistical reviewer's questions, writing the statistical sections of briefing documents ahead of end-of-phase or pre-NDA meetings, and sometimes presenting directly in an advisory committee meeting are all part of the job at the submission stage.
This is where the discipline differs most from a purely academic statistics career. The questions aren't abstract; they're "why did you handle this missing data pattern this way, and would the conclusion change under a different assumption." Sensitivity analyses — rerunning the primary analysis under alternative, reasonable assumptions — exist precisely so a biostatistician has a ready answer when that question comes.
Estimands and the ICH E9(R1) Shift
A meaningful change in the discipline over the past several years has been the adoption of the estimand framework under ICH E9(R1). Rather than simply specifying a statistical test, trial teams now have to state up front, in plain terms, exactly what question a given analysis is answering — what happens to patients who stop treatment, switch to rescue medication, or are lost to follow-up, and whether the analysis is estimating the effect of assignment to treatment or the effect of actually taking it as directed.
This forces earlier, more explicit conversations between biostatisticians, clinicians, and regulatory strategists about what a trial is actually meant to show — conversations that used to happen implicitly, if at all, buried inside a choice of analysis method. Fluency with estimand thinking is now something hiring managers specifically probe for in interviews.
Where the Role Sits, and How People Get Into It
Biostatistics functions are organized differently across companies. Some sponsors house biostatistics inside a broader "biometrics" department alongside data management and statistical programming; others keep it embedded within clinical development. CROs employ large pools of biostatisticians who work across multiple sponsors' trials simultaneously, which is a common and reasonable entry route for people early in the field, since CRO assignments expose you to a wider range of therapeutic areas and trial designs faster than staying inside one sponsor's pipeline.
The standard academic path is a master's or doctoral degree in biostatistics or statistics, sometimes with a public health or epidemiology concentration. A PhD is common in roles that involve novel trial design or direct regulatory negotiation; a master's degree is sufficient for many analysis-execution roles, particularly at CROs. SAS programming certification helps candidates without it stand out, since fluency in SAS remains an industry expectation even as R adoption grows, especially for submission-ready outputs that still favor SAS's validated output traceability.
Skills Hiring Managers Are Looking For Right Now
- Adaptive and Bayesian design experience — trials that modify sample size, dose arms, or randomization ratios based on accumulating data require statisticians comfortable outside the fixed-design playbook.
- Estimand framework fluency under ICH E9(R1), as described above.
- CDISC/ADaM standards literacy, even for biostatisticians who don't write the programming code themselves, since reviewing and specifying these datasets correctly is now a baseline expectation.
- Comfort working directly with regulatory strategists on submission content, not just handing off a finished analysis.
- Cross-functional communication — translating a sensitivity analysis or a missing-data assumption into language a clinical operations lead or a company's leadership team can actually act on.
How the Career Ladder Typically Runs
Most sponsors and CROs structure biostatistics on a fairly standard ladder: an associate or entry-level biostatistician works under supervision on a single study's analyses, typically for two to four years before taking on independent trial ownership. A biostatistician or senior biostatistician owns the statistical strategy for one or more trials outright, writing SAPs and defending them to regulators directly. Beyond that, a principal or director-level biostatistician usually oversees statistical strategy across an entire development program or therapeutic area, mentors junior staff, and represents the function in cross-functional leadership discussions about trial design trade-offs.
A smaller number of biostatisticians move into methodological or innovation-focused roles — building out a company's capability in adaptive designs, Bayesian methods, or quantitative decision-making frameworks that span multiple programs rather than sitting inside any one trial. These roles tend to go to people with a PhD and a strong publication or methods-development track record, and they're as close as the discipline gets to a pure research career inside an industry setting.
Conclusion
Clinical trial biostatistics rewards people who like the discipline of getting an argument airtight before anyone can poke a hole in it. The SAP, the sample size calculation, the interim analysis firewall, and the regulatory response letters are all expressions of the same underlying habit: deciding the rules before you know the answer, so the answer means something when it arrives. For anyone weighing a move into clinical development from a quantitative background, it's worth knowing that this is one of the few roles in the field where the math itself, not just the process around it, is the daily work.

Regulatory & Quality. REWIRED.
New roles. Real pay. Your next move.
- Hand-picked roles, every week.
- The newest company pages.
- One article worth your time.
Free. Thursday mornings. One-click unsubscribe.
Find your next regulatory or quality role
Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.





